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1. Introduction 
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death 
in females worldwide [1]. Over 1.1 million cases of breast cancer are diagnosed across the 
world each year, compared with about 500,000 cases in 1975. This represents about 10% of 
all new cancer cases and 23% of all female cancers [2-3]. An annual prevalence of more than 
4.4 million cases of breast cancer is expected worldwide by the year 2012 [4].  
In the past years, our knowledge of the genetic changes that contribute to breast cancer 
development & progression has tremendously changed [5]. Our knowledge of alterations in 
the cancer cell have allowed us to identify the signaling pathways that when disrupted 
allow a cancer cell to escape from normal control mechanisms [6]. On the other hand, these 
aberrant processes have also provided many therapeutic points for intervention, which is 
the major topic of this chapter. Following the successful introduction of trastuzumab, the 
first human epidermal growth factor receptor (HER) targeted therapy to become widely 
used in breast cancer patients, other agents have been developed [7]. Other potential 
hallmarks of malignancy that represent a new opportunity for therapeutic targeting include 
abrogation of apoptosis, lack of senescence, angiogenesis, tumor invasion and metastasis [8]. 
Therefore, new compounds are being developed that may interfere with these hallmarks 
and that may prove to be effective in monotherapy or in combination with cytotoxic therapy 
or other targeted therapies. Novel agents are needed because many of the current therapies 
have limitations. These include drug resistance, lack of target receptor expression in tumors 
and relatively small improvements in survival [9-12].  
Thus, this chapter provides an updated overview of the several signaling transduction 
pathways involved in development of breast cancer. In addition, it focuses on recent 
progress with the therapeutic strategies targeting these pathways contributing to their 
promising success in the clinical setting. Furthermore, molecular signals of its resistance 
phenotype and breast cancer stem cells & their therapeutic targeting are discussed briefly. 
Finally, the challenges facing the significant contribution of targeted therapeutics in breast 
cancer chemotherapy are also extensively discussed. Wherever possible, advances in drug 
analogs, accepted or controversial mechanisms described for their antitumor activity will be 
discussed within the framework of the current chapter.  
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Section A describes a reported panel of potential signal transduction pathways (STPs) that are 
altered in breast cancer and are undergoing research as targeted therapeutics. Some of these 
have yielded therapeutics that already had clinical success, while others are still in the 
experimental stages (Fig. 1 & Tab.1). Though many of the underlying mechanisms of the 
multi-drug resistance (MDR) phenotype are still not clearly identified, several potential 
molecular targets and pathways of activation have been suggested. The advances in this field 
provide an emerging picture of how MDR arises and how it could be therapeutically targeted. 
In Section B, we review the potential role of cancer stem cells molecular signaling in 
development of breast cancer & its resistance phenotype. It also discusses their putative 
modulation contributing to the success of targeted therapeutics in breast cancer chemotherapy. 
 
 STP STI Mechanism 
1 
Receptor tyrosine 
Kinase: 
I- HER2 receptor 
-Trastuzumab 
 
 
 
-Lapatinib, Erlotinib, 
Gefitinib and Neratinib 
-Extracellular Targeted Therapeutic: 
Monoclonal Antibody inhibiting 
ligand binding to receptor 
-Intracellular Targeted Therapeutic: 
HER Receptor tyrosine kinase 
catalytic inhibitor 
Receptor tyrosine 
Kinase: 
II- Src receptor 
Dasatinib 
Intracellular Targeted Therapeutic: 
Src Receptor tyrosine kinase catalytic 
inhibitor 
2 
MAPK Signaling 
Pathway 
Tipifarnib 
Farnesyl transferase inhibitor 
3 
PI3K/Akt/mTOR 
pathway 
-Perifosine 
-Temsirolimus and 
Everolimus 
-Octreotide 
-Inhibitor of Akt phosphorylation 
-mTOR inhibitors 
 
-Inhibitor of IGF-1R signaling 
4 
HSP90 signaling 
pathway 
Tanespimycin and 
Alvespimycin 
Potent inhibitiors of HSP90 function 
5 
PARP signaling 
pathway 
Olapraib 
Veliparib 
PARP inhibitors 
6 
Apoptosis & Autophagy 
pathways 
 
Inhibitors of the components of 
apoptotic & autophagic pathways 
7 Angiogenesis Bevacizumab 
Extracellular Targeted Therapeutic: 
Monoclonal Antibody inhibiting 
ligand binding to receptor 
 
8 
Multi-Target 
Therapeutics 
Sunitinib, Pazopanib, 
Sorafenib and Axitinib 
Intracellular Targeted Therapeutic: 
Receptor tyrosine kinase catalytic 
inhibitors 
9 
Estrogen signaling 
transduction 
-Tamoxifen 
-Letrozole 
-Anti-estrogen 
-Aromatase inhibitor 
10 UPS signaling pathway Bortezomib Proteasome inhibitor 
Table 1. A list of the action site for signal transduction inhibitors (STIs) in breast cancer. 
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Fig. 1. Simplified schematic illustration of the multiple signal transduction pathways (STPs) 
in breast cancer. 
2. Targeting signal transduction pathways in breast cancer 
The mechanisms underlying the development of breast cancer are complex and vary among 
individual tumors [13]. Altered patterns of gene expression are associated with 
corresponding variations in growth rates, cellular composition and different prognoses [14]. 
Given the complex and varied factors that influence the development of breast cancer, and 
the use of increasingly sophisticated genetic analysis techniques, it is likely that more 
refined tumor subtypes and their associated prognoses will be identified[13, 15]. Advances 
in the understanding the etiology and biology of breast cancer have identified key targets 
among multiple signaling pathways involved in the development and survival of breast 
cancer cells. Thus, targeted therapies are among the most promising new agents for the 
treatment of breast cancer. Some of these reported breast cancer signaling transduction 
pathways (STPs) & their signal transduction inhibitors (STIs) are classified as follows: 
2.1 STPs-1: Receptor Tyrosine Kinase (RTKs) 
Altered patterns of gene expression can influence the activity of specific signaling pathways. 
For example, receptor tyrosine kinases (RTKs) are often aberrantly over-expressed or 
activated in human cancers. The epidermal growth factor receptor (EGFR) family is 
composed of cell surface tyrosine kinase receptors that are involved in the regulation of 
cellular proliferation and survival of epithelial cells. The EGFR (or also called HER) family 
includes four closely related receptors: EGFR/HER1/ErbB1, HER2 neu /ErbB2, 
HER3/ErbB3 and HER4/ErbB4 [16]. 
2.1.1 HER2 receptor 
Members of the HER family are encoded by genes on different chromosomes and regulate 
normal breast growth and development. The HER family couples to multiple signaling 
Target 
Transcriptional 
Machinery
Signal Transduction 
Pathways (STPs)
EgR
VEGFR
EGFR/HER
SrcR
Angiogenesis
ProliferationAdhesion/
Metastasis
Autophagy
Survival/
Apoptosis 
Inhibition
Intra-cellular 
STIs
Extra-cellular 
STIs
Extra-cellular 
STIs
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pathways that impact on all aspect of breast cancer biology. Through their interconnected 
cellular signaling network, the HER family regulates diverse biological processes, including 
cell proliferation, differentiation, and survival [16-17]. Thus, they play a key role in the 
development and progression of breast cancer [16, 18-19]. 
Variations in the pathways associated with the HER family appear to be particularly 
important, not only in tumor development but also in treatment efficacy [20-21]. For 
example, in breast cancer, constitutive activation of the epidermal growth factor receptor 
(EGFR) and HER2 is found in approximately 16%–48% and 25%–30% of breast cancer 
tumors, respectively. Moreover, expression of HER family members in breast cancer tumors 
has a significant impact on tumor aggressiveness and patient survival. Importantly, their 
expression correlates with a more aggressive disease course, shorter survival time, and 
higher risk for resistance to endocrine therapies [10, 12, 22-27]. HER-3 expression, observed 
in approximately 18% of tumors, also correlates with shorter overall survival [28]. 
Interestingly, expression of HER-4 (found in approximately 12% of tumors) has been 
associated with more favorable tumor characteristics and longer survival [27-28]. 
Each HER receptor has an extracellular domain (ECD) involved in ligand binding, a helical 
transmembrane segment, and an intracellular protein domain with tyrosine kinase activity. 
On ligand binding, the extracellular domains of the receptors undergo conformational 
changes, which allows them to form homodimers (consisting of two identical receptors) or 
heterodimers (consisting of two different receptors) of the HER family [16, 29]. Dimerization 
of HER receptors induces phosphorylation of their intracellular tyrosine kinase domains, 
which provide docking sites for adaptor proteins and signaling enzymes [29].These 
molecules act as a link between membrane receptor kinases and “downstream” intracellular 
protein kinases, which results in the activation of multiple signaling pathways, of which the 
MAPK and PI3K pathways are probably the best studied [29]. 
HER-2 is the preferred dimerization and signaling partner for all other members of the HER 
family, and it appears to function mainly as a co-receptor, increasing the affinity of ligand 
binding to dimerized receptor complexes [29-30]. With their multiple ligands, many 
dimerization combinations, and large number of downstream effectors, the HER family 
mediates an extensive range of signals, controlling a variety of cellular processes, including 
cellular proliferation, apoptosis, and angiogenesis [29, 31]. For example, HER2 receptor 
activation leads to the phosphorylation of the intracellular catalytic domains, and ultimately 
activation of signal transduction pathways that promote proliferation and survival, 
including the phosphatidylinositol 30-kinase (PI3K)/Akt/mTOR, the Erk1/2 
mitogenactivated protein kinase (MAPK) and the Jak/Stat pathway [32]. 
2.1.2 Src-family tyrosine kinases 
The v-Src (Rous sarcoma virus) tyrosine kinase was the first oncogenic gene discovered [33]. 
The corresponding cellular gene, c-Src, is a non-receptor signaling kinase that functions as a 
hub of a vast array of signal transduction pathways that influence cellular proliferation, 
differentiation, motility and survival [34]. Several mechanisms lead to increased Src activity 
in tumors. Src is downstream in signaling from a number of growth factor receptors 
including PDGF receptor (PDGFR), epidermal growth factor receptor (EGFR) and insulin-
like growth factor- 1 receptor (IGF-1R) [35].  
In many tumor types, over-expression of these receptors, their ligands or both is frequent 
[36]. For example, reported studies suggest an association between Src tyrosine kinase and 
the development, progression and metastasis of breast cancer [37-38]. In addition, it is 
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described that mice over-expressing the HER2 oncogene develop highly metastatic 
mammary tumors with elevated Src activity [37]. Further supporting the role of Src in breast 
cancer, it has been demonstrated that Src activity is profoundly increased in human breast 
cancer tissues compared with benign breast tumors or adjacent normal breast tissues[38-39] 
and that elevated c-Src tyrosine kinase activity is correlated with early systemic relapse [40]. 
Taken together, these results strongly indicate that the Src may play an important role in the 
development and progression of breast cancer [41]. 
2.2 STIs-1: Receptor Tyrosine Kinase Inhibitors (RTKIs) 
2.2.1 HER2 receptor inhibitors 
Numerous agents targeting individual members of the HER family have been developed for 
use in the treatment of breast cancer. Existing therapeutic approaches have largely focused 
on two classes of agents: 
2.2.1.1 Extracellular targeted therapies 
Monoclonal antibodies 
The first comprises monoclonal antibodies that bind to extracellular regions of HER to 
interfere with receptor function (e.g., trastuzumab, pertuzumab, and a number of pan-HER 
inhibitors). Trastuzumab binds to the juxtamembrane region of HER-2 with high specificity, 
but it is not currently known how it specifically interferes with HER-2 function [42]. 
Pertuzumab is the first in a class of HER-2 dimerization inhibitors. Binding to HER-2 
inhibits its dimerization with other HER receptors and this is thought to result in slowed 
tumor growth [43].  
Trastuzumab, an HER2 specific humanized monoclonal antibody was one of the first 
biologicals to be approved for metastatic breast cancer treatment [44]. In patients, HER2 is 
over-expressed and/or amplified in one-fourth of breast tumors and confers a more 
aggressive clinical course and a worse survival [25, 45]. The outcome of these highly 
aggressive tumors has markedly improved with the development of anti-HER2 therapies. 
Trastuzumab (Herceptin®) is a recombinant humanised monoclonal antibody that binds 
with high affinity to the extracellular juxtamembrane domain of HER2 and inhibits the 
proliferation of human tumor cells that over-express HER2 in vitro and in vivo [46-48]. 
Trastuzumab. Trastuzumab, administered as an i.v. infusion, is approved in the U.S. and 
Europe for the treatment of HER-2–over-expressing metastatic breast cancer (MBC) [7]. It is 
standard-of-care treatment for MBC patients with HER-2–over-expressing tumors, both as 
first-line treatment in combination with chemotherapy and as a single agent in women who 
have HER-2–over-expressing breast cancer that has progressed after chemotherapy for 
metastatic disease[44, 49]. Trastuzumab is approved for the adjuvant treatment of HER-2+, 
node negative (ER-/progesterone receptor [PgR-]) or node-positive breast cancer, either in 
combination with chemotherapy or as a single agent following multi-modality 
anthracycline-based treatment. 
In patients with HER2 amplified tumors, trastuzumab has single agent activity and 
improves survival in the first-line setting when combined with chemotherapy in patients 
with advanced disease [44, 50]. Recently, a number of well powered clinical trials have 
demonstrated that administration of trastuzumab in the adjuvant setting, in combination 
and/or sequentially after chemotherapy, results in an improvement in disease-free survival 
as well as overall survival [51-54]. 
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Trastuzumab efficacy in the metastatic setting has provided the rationale for several studies 
investigating the use of trastuzumab plus chemotherapy as adjuvant treatment for patients 
with earlystage HER-2+ breast cancer [52-53, 55-56]. Studies have evaluated a range of 
different trastuzumab-based combination regimens for the first-line treatment of MBC [50, 
57]. Additionally, a number of trials are ongoing investigating trastuzumab in combination 
with hormonal therapy in MBC patients [58-59]. When administered as a single agent, 
trastuzumab has documented efficacy as a first-line therapy, with response rates typically in 
the range of 23%–33% [60-62]. Of those patients with MBC who do achieve an initial 
response, many experience disease progression within 12 months as a result of the high 
proportion of HER-2–over-expressing tumors that have intrinsic resistance to this agent [63]. 
Given the absence of known specific ligands for HER-2, thus there is no alternative 
approach to blocking this pathway except by trastuzumab. This has clinical implications as 
this may be related to the development of resistance to HER-2 blockade [64]. 
On the other hand, changing the traditional treatment paradigm in patients progressing on 
trastuzumab and administering further trastuzumab-based therapy beyond disease 
progression may have clinical benefit [65-66].This “treatment beyond progression” approach 
is increasingly being studied in clinical trials by combining trastuzumab either with 
chemotherapy [67-68] or with another targeted agent, such as the RTKI lapatinib [69]. 
Trastuzumab-DM1 (T-DM1) is an anti–HER-2 antibody drug conjugate comprising 
trastuzumab linked to the maytansine derivative DM1. Combining these two agents 
facilitates anti–HER-2 activity as well as targeted intracellular delivery of a potent cytotoxic 
agent. Single-agent TDM1 as well tolerated, active and no dose-limiting cardiotoxicity was 
observed in a phase II study of 112 patients with pretreated MBC [7]. 
Limitations of Trastuzumab therapy 
1. Trastuzumab is an effective treatment for patients with HER-2+ disease, yet its use is 
limited to this group (approximately 25%) [25]. Thus, accurate patient selection for 
treatment is important, using an appropriate method, such as immunohistochemistry or 
fluorescence in situ hybridization, to detect HER-2 over-expression.  
2. Not all HER-2+ patients respond to treatment with trastuzumab, and the development 
of resistance is an issue. In the future, it may be possible to overcome resistance by 
combining trastuzumab with new therapies such as pertuzumab, by switching to an 
agent such as lapatinib that inhibits both HER-1 and HER-2 activity, or, if proven 
effective, the use of one of the pan-HER inhibitors currently in development.  
3. Trastuzumab is unable to penetrate the blood– brain barrier (Guy et al., 1994) and over-
expression of HER-2 is known to be associated with a greater risk for central nervous 
system (CNS) metastases [70]. Patients with HER-2+ MBC treated with trastuzumab 
appear to be at greater risk for developing CNS metastases than those who do not 
receive trastuzumab therapy [71]. However, HER-2+ patients with CNS metastases who 
are treated with trastuzumab appear to have a longer overall survival duration than 
those who are HER-2- or those unselected for HER-2 status. This may reflect greater 
control of extra-cranial disease as a result of trastuzumab therapy [72]. 
4. Treatment with trastuzumab is associated with a higher risk for cardiomyopathy (left 
ventricular dysfunction and congestive heart failure), particularly when used in 
combination with paclitaxel or anthracyclines [73]. However, these cardiotoxic effects 
appear to be reversible once trastuzumab treatment is discontinued or if they are 
managed with appropriate medical therapy [74-75]. The cellular mechanisms 
contributing to the cardiotoxicity observed with trastuzumab are still being explored. It 
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is known that HER-2 plays an important role in cardiomyocyte development and 
function, and trastuzumab- induced inhibition of HER-2 signaling in cardiomyocytes 
may be a central mechanism underlying the observed cardiomyopathy. However, the 
full explanation is likely to be more complex. Cardiotoxicity does not appear to be an 
issue with the RTKI lapatinib, which inhibits both HER-1 and HER- 2 [76] 
5. Although cardiotoxicity is the primary safety concern with trastuzumab, potentially 
severe hypersensitivity reactions to infusion have also been reported [7]. 
Other example of novel anti-HER2 agents include antibodies that interfere with HER2 
dimerisation. Pertuzumab is a recombinant, humanised MAb that targets an epitope within 
the HER2 dimerisation domain [77]. Once bound, pertuzumab inhibits ligand-activated HER 
dimerisation with HER2 and thereby inhibiting activation of intracellular signaling [78]. 
2.2.1.2 Intracellular targeted therapies  
Receptor tyrosine kinase inhibitors (RKIs) 
The second class of HER-targeted agents comprises the small molecule receptor tyrosine 
kinase inhibitors (RTKIs) that inhibit enzyme function of HER family members 
intracellularly. Oral RTKIs include lapatinib, neratinib (both inhibit HER-1 and HER-2), 
erlotinib and gefitinib that target the intracellular domain of HER-1, and the irreversible 
pan-HER inhibitors PF-00299804 and canertinib, which inhibit the kinase signaling of 
multiple HER family members [79]. 
Another strategy to target HER2 is with low molecular weight tyrosine kinase inhibitors. 
Lapatinib (Tykerb®) is a dual EGFR and HER2 inhibitor that has been studied extensively in 
multiple clinical settings. Lapatinib is approved in the U.S. (March 2007) and European 
Union (EU) (June 2008) for use (oral administration) in combination with capecitabine for 
the treatment of patients with advanced breast cancer or MBC whose tumors over-express 
HER-2 and who have received prior therapy including an anthracycline, a taxane, and 
trastuzumab [7]. 
Lapatinib increases survival in patients with advanced HER2-over-expressing breast cancer 
when given in combination with the chemotherapeutic agent capecitabine compared to 
capecitabine alone in patients that had previously failed anthracyclines and taxanes [80]. 
The incidences of adverse events (including those leading to treatment discontinuation) and 
symptomatic cardiac events were similar in both treatment groups. The observation that 
fewer patients in the lapatinib group developed central nervous system (CNS) metastases 
together with lapatinib’s low molecular weight and capacity to cross the blood-brain barrier 
has led to a clinical trial to study the role of lapatinib in the treatment of brain metastasis in 
patients with HER2-over-expressing breast cancer [25, 28]. Thus, contrary to trastuzumab, 
lapatinib has a putative activity against CNS metastases in patients with HER-2+ breast 
cancer [81]. These data suggest that, as a small molecule RTKI, it may be able to cross the 
blood– brain barrier to provide effective therapeutic concentrations in cerebrospinal fluid 
(unlike monoclonal antibodies such as trastuzumab). 
Lapatinib appears to be associated with less cardiotoxicity than trastuzumab [82]. However, 
as lapatinib development is extended to include the treatment of patients with lower-risk 
primary breast cancer, it will be increasingly important to monitor cardiotoxic effects. The 
most common adverse effects associated with lapatinib treatment are gastrointestinal; 
lapatinib-related diarrhea generally occurs early in the course of treatment, is mild to 
moderate, and does not require treatment, although monitoring is important to identify 
patients who may need intervention [7]. 
www.intechopen.com
 
Breast Cancer – Carcinogenesis, Cell Growth and Signalling Pathways 116 
Other examples of RTKIs include Erlotinib and Gefitinib. Recent clinical studies have not 
demonstrated any significant clinical benefit for erlotinib or gefitinib either as single agents 
or in combination with other agents in MBC [68, 83-85]. Given their lack of activity as 
monotherapy in MBC, studies continue to investigate the efficacy of erlotinib and gefitinib 
in combination with other targeted therapies, chemotherapy, or hormonal agents; however, 
tolerability issues may limit this approach. 
Other anti-HER tyrosine kinase inhibitors in clinical development include HKI-272. 
Neratinib (HKI-272) is an orally administered, irreversible, pan-erbB kinase inhibitor [86] 
that covalently bind to the intracellular kinase domain. The observation that some patients 
with chronic myelogenous leukemia were developing resistance to the RTKI imatinib led to 
the development of neratinib. In preclinical models, neratinib has been shown to have 
promising antiproliferative activity in both HER-2–dependent cell lines and tumor 
xenografts. 
Phase I/II data have confirmed that neratinib has antitumor activity in patients with HER-
2+ MBC, either as a single agent in trastuzumab refractory patients or in combination with 
trastuzumab, and the safety profile of this agent has been manageable [87]. 
2.2.2 Src-family tyrosine kinases inhibitors 
Currently, small-molecule Src inhibitors are in early phases of clinical development either 
as single agents, in combination with cytotoxic agents, biological therapies or in 
combination with hormonal treatment. Originally, dasatinib (BMS-354825) was selected as 
a synthetic small-molecule inhibitor of Src-family kinases; then, it was found to inhibit at 
least four other protein tyrosine kinases: bcr-abl, c-Kit, EphA2, PDGF-beta. Dasatinib is 
currently studied in clinical trials for the treatment of solid tumors, including breast 
cancer. Preclinical evidence suggests that dasatinib could be effective in breast cancer cell 
lines of basal-like subtype [88]. These findings provide scientific rationale for the clinical 
development of dasatinib in the treatment of patients with ‘triple-negative’ breast cancer, 
a tumor subtype that is categorised as being aggressive and lacking effective targeted 
treatments, such as endocrine therapies and anti- HER2 strategies. More recently, AZD-
0530 a highly selective, dual-specific, orally available small-molecule inhibitor of Src 
kinase and Bcr-Abl has entered clinical trials [89]. In healthy volunteers, AZD-0530 has 
shown only mild adverse events.  
Targeting downstream effector molecules 
Targeting HER receptors with extracellular monoclonal antibodies and intracellular RTKIs 
has shown promising clinical activity. There is, however, a need for better treatment of MBC 
patients because many of these current therapies are restricted to a subset of the MBC 
patient population. Targeting cellular signaling pathways, such as the MAPK and PI3K 
pathways, downstream of HER receptors may be an attractive avenue for novel treatments. 
Additionally, there is some evidence that targeting heat shock proteins (Hsps) and the 
apoptotic pathway may be viable options for future therapeutic strategies in MBC. Recent 
developments in this field are briefly discussed in the following sections. 
2.3 STPs-2: Targeting downstream MAPK signaling pathway  
The MAPK pathway, also termed the extracellular signal-regulated kinase (ERK) pathway, 
contains downstream effectorsof the HER family and other tyrosine kinases, and is a central 
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part of the signaling networks that control fundamental cellular processes, including cell 
proliferation, differentiation, and survival [90]. 
2.4 STIs-2: Targeted therapies directed at the MAPK signaling pathway 
The farnesyl transferase inhibitor tipifarnib (R115777) was evaluated in phase III trials for 
the treatment of breast cancer, although further development has now been terminated  
[91-93]. AZD6244 (ARRY-142886) is an inhibitor of the enzyme MEK, a component of the 
MAPK pathway. AZD6244 is currently in phase I clinical studies in several cancer types, 
including breast cancer. 
2.5 STPs-3: Targeting downstream PI3K/Akt/mTOR pathway signaling pathway  
The PI3K/Akt pathway plays a central role in diverse cellular functions including 
proliferation, growth, survival and metabolism. In addition to their physiological role, 
several isoforms of the PI3K family are implicated in tumor development, including cell 
proliferation, cell growth, cell motility, cell survival, and angiogenesis [29]. The relationship 
between dysregulated PI3K activity and the onset of cancer is well documented [94]. In 
particular, members of class 1A PI3Ks are often mutated in human cancer [95-100]. As a 
result of receptor tyrosine kinase RTK activation and phosphorylation, PI3K interacts with 
the intracellular domain of the receptors. Subsequent phosphorylation event by the 
mammalian target of rapamycin (mTOR)-complex is required for maximal Akt activity [101-
102]. Akt is the central effector of the pathway. Akt reduces cell cycle inhibitors p27 and p21, 
and promotes cell cycle proteins c-Myc and cyclin D1, resulting in enhanced cellular 
proliferation. Its influence extends to a host of pro- and antiapoptotic proteins, such as the 
Bcl-2 family member Bad, limiting programmed cell death and boosting cellular survival. 
mTOR is a central regulator of cellular responses to multiple stimuli including amino acid 
availability and growth factor receptor signaling. In cells with sufficient nutrients, mTOR 
relays a signal to the translational machinery leading to an enhanced translation of mRNAs 
encoding proteins essential for cell growth and cell cycle progression [103-104]. 
There is growing evidence that uncontrolled activation of the phosphatidylinositol 3-kinase 
(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, achieved via numerous 
genetic and epigenetic alterations, contributes to the development and progression of 
human cancers, including breast cancer [105]. In breast tumors, activating mutations in 
PIK3A, encoding the catalytic subunit of PI3K, or loss of PTEN, the negative regulator of 
PI3K activity, are very frequent and contribute to constitutive pathway activation and 
mTOR activity. Further, they may result in resistance to upstream anti-receptor agents. For 
example, trastuzumab depends on intact PTEN for its action in HER2-over-expressing 
breast cell lines, and PTEN loss predicts for trastuzumab resistance [106]. Therefore, this 
pathway is an attractive target for novel anticancer agents. Clinical trials are currently 
underway with mTOR, PI3K and Akt inhibitors. 
2.6 STIs-3: Inhibitors of the PI3K/Akt/mTOR pathway 
Therapies targeting the PI3K pathway include perifosine (KRX-0401), which inhibits Akt 
phosphorylation [107] and mTOR inhibitors are also further ahead in development within 
this class of agents. The rapamycin analogs that target mammalian target of rapamycin 
include temsirolimus (CCl-779) [108-109]. Rapamycin derivatives such as everolimus, 
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temsirolimus and deforolimus are potent inhibitors of mTOR and do not share the problems 
of poor solubility and chemical stability of rapamycin. 
Recent data from two phase I trials suggest that everolimus can help overcome resistance to 
trastuzumab in women with HER-2+ MBC. Everolimus plus trastuzumab and weekly 
paclitaxel was shown to slow tumor growth in 77% of patients, and the combination of 
everolimus with trastuzumab and vinorelbine halted tumor growth in 62% of patients [110-
111]. Although early indications suggest that targeting components of the PI3K pathway 
may have some activity in the treatment of MBC, additional data, including an 
understanding of combinations and patient selection, are required. 
However, in unselected patients with breast cancer these agents have modest anti-tumor 
activity in the range of around 10% [112]. There is therefore a need to identify the subset of 
patients that may benefit from it, and PI3K/Akt/mTOR-dependency genetic signatures are 
being developed. In this direction, it has been recently observed that a majority of locally 
advanced and inflammatory breast cancers over-express the translation regulatory 
protein4E-BP1 and the initiation factor eIF4G, both of them are mTOR downstream targets. 
While additional studies are planned to further dissect this interaction, it does seem 
reasonable to explore the benefits of mTOR inhibitors in the treatment of locally advanced 
breast cancer [113]. 
Another potential explanation for the limited activity of mTOR inhibitors in breast cancer 
and other tumor types may be related to a ‘collateral effect’ of mTOR blockade. mTOR 
inhibition blocks the natural negative feed-back on IGF-1R signaling exerted on PI3K [114]. 
The result is an increase in PI3K and Akt activations which could potentially counteract the 
inhibition of mTOR. Thus, dual inhibition of both IGF-1 signaling, with either MAbs against 
the receptor or tyrosine kinase inhibitors, and mTOR results in superior anti-proliferative 
effect over each single strategy.  
In the clinic there is indirect evidence that this approach may be fruitful as well. Octreotide 
has been shown to inhibit IGF-1R signaling. Although octreotide has limited activity in 
patients with refractory neuroendocrine tumors, it has been shown to that the combination 
of everolimus and octreotide has resulted in an impressive activity [115].  
2.7 STPs-4: HSP90 signaling pathway 
Heat shock protein 90 (HSP90) is a molecular chaperone required for the stability and 
function of several conditionally activated and/or expressed signaling proteins ([116-117]. 
Many of these client proteins such as Akt, HER2, Bcr-Abl, c-Kit, EGFR and PDGFR-a are 
oncoproteins and important cell-signaling proteins [118-119]. As signal transducers and 
molecular switches, these client proteins are inherently unstable. HSP90 keeps unstable 
signaling proteins poised for activation until they are stabilised by conformational changes 
associated with the formation of signal transduction complexes. As such, it is a single 
molecular target that is a central integrator of multiple pathways important to cancer. 
Activation of HSP90-dependent client proteins proceeds through an ordered sequence of 
events linked to the ATPase activity of HSP90 and involves a variety of co-chaperone 
complexes [120]. 
HER2 is among the most sensitive client proteins of HSP90, demonstrating degradation 
within 2 h of HSP90 inhibition in cell culture experiments [121]. Geldanamycin analogues 
(17-allylamino- 17-demethoxygeldanamycin [17-AAG] and 17-dimethylaminoethylamino- 
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17-demethoxygeldanamycin [17-DMAG]) have demonstrated potent inhibition of HSP90 
function in HER2-over-expressing cell lines, demonstrating significant anti-tumor activity in 
both cell culture and animal studies [121-122]. 
2.8 STIs-4: HSP90 inhibitors 
(HSP90) is an exciting new therapeutic target, inhibition of which delivers a combinatorial 
attack on multiple oncogenic targets and pathways and on all of the hallmark traits of 
malignancy [123]. In the clinic, initial studies with the HSP90 inhibitor have demonstrated 
safety and anti-tumor activity and tolerability in combination with trastuzumab in patients 
with trastuzumab-refractory HER2- positive metastatic breast cancer patients [120]. It will be 
important to determine whether HSP90 inhibitors will have clinical activity as single agents 
in breast cancer patients. 
2.9 STPs-5: PARP signaling pathway 
Poly (ADP-ribose) polymerase 1 (PARP-1) is the initial and best characterised member of a 
family of enzymes largely associated with the maintenance of genomic stability. Activation 
of PARP-1 is part of the immediate cellular response to DNA strand breaks, converting them 
into an intracellular signal via poly (ADP-ribosylation) of nuclear proteins [124-125]. This 
results in a highly negatively charged target, which in turn leads to the unwinding and 
repair of the damaged DNA through the base excision repair pathway. In addition, PARP-1 
is also known to bind dsDNA breaks (DSB) preventing accidental recombination of 
homologous DNA [126]. Upon binding DNA breaks, the catalytic activity of PARP-1 is 
stimulated >500- fold [127]. Enhanced PARP-1 expression or activity has been also observed 
in a number of different tumor cell lines and could provide a greater level of resistance to 
both endogenous genotoxic stress and to DNA damage-inducing therapeutic agents. 
Studies of PARP expression in various tumor types identified that breast cancers with 
negative estrogen receptor, progesterone receptor and HER2 expression were much more 
likely to over-express PARP [128]. Additionally, it has been recently shown that BRCA1 and 
BRCA2 dysfunction sensitises cells to the inhibition of PARP enzymatic activity, resulting in 
chromosomal instability, cell cycle arrest and subsequent apoptosis. This seems to develop 
because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by 
homologous recombination [128]. 
2.10 STIs-5: PARP inhibitors 
PARP inhibitors have been developed to investigate the role of PARP-1 in cell biology and 
to overcome DNA repair-mediated resistance of cancer cells to genotoxic agents [129]. These 
novel PARP inhibitors have been shown to enhance the anti-tumor activity of DNA-
methylating agents, such as temozolomide, topoisomerase poisons and ionising radiation in 
preclinical studies [130], and to restore sensitivity of resistant tumors to methylating agents 
or topoisomerase I inhibitors, agents presently used for the treatment of breast cancer.  
2.11 STPs-6: Apoptosis & autophagy signaling pathways  
Apoptosis, the process of programmed cell death, is governed by complex, gene-directed 
pathways [131-133]. Dysregulation of apoptosis plays a key role in tumorigenesis and can 
allow tumor cells to become resistant to anticancer treatments [132-133]. Rationale for 
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targeting apoptosis in the treatment of breast cancer includes the over-expression of the 
Bcl-2 protein in 40%–80% of human breast tumors, which is associated with both 
resistance to chemotherapy [134] and a better prognosis after chemotherapy [135]. 
Additionally, the association of Bcl-2 with ER and/or PgR, loss of expression of the gene 
for the pro-apoptotic protein Bax, and differential expression of tumor necrosis factor–
related apoptosis-inducing ligand-receptor 2 have all been correlated with prognosis in 
breast cancer patients [134-137]. 
On the other hand, autophagy is an evolutionarily conserved lysosomal pathway for 
degrading cytoplasmic proteins, macromolecules, and organelles [138]. Many studies have 
described the role of autophagy as a protective mechanism for cell survival that is initiated 
in response to metabolic or therapeutic stress. Furthermore, autophagy may delay apoptotic 
cell death caused by DNA damaging agents and hormonal therapies [139-141]. 
2.12 STIs-6: Targeted therapies directed at the apoptotic & autophagic pathways 
Anticancer agents targeting the components of apoptotic pathways are in the early  
stages of development, and no agent specifically targeting apoptosis has yet been 
approved for use in cancer treatment. A range of approaches is being tested, including 
antisense DNA oligonucleotides and antibody and small molecule inhibitors of the 
components of apoptotic pathways. Few clinical data are currently available in breast 
cancer; however, preclinical studies show that such agents do have anticancer activity, 
suggesting that this may be a promising approach, particularly when used in combination 
with chemotherapy [7]. 
On the other hand, recent studies have demonstrated that the inhibition of autophagy in 
cancer cells may be therapeutically beneficial in some circumstances, as it can sensitize 
cancer cells to different therapies, including DNA-damaging agents, antihormone therapies 
(e.g., tamoxifen), and radiation therapy. This supports the hypothesis that inhibiting 
autophagy can increase cell death when combined with anticancer agents, providing a 
therapeutic advantage against cancer proliferation & drug resistance [139-141]. 
2.13 STPs-7: Targeting the angiogenesis pathway 
It is increasingly being accepted that tumor cell proliferation alone is insufficient to result in 
a substantial tumor mass. Angiogenesis is essential for tumors to develop into detectable 
localized masses, and for metastasis to occur [142-143]. The process of angiogenesis (the 
formation of new blood vessels from a pre-existing vascular bed) is complex and dynamic, 
and it is regulated by a range of pro- and anti-angiogenic molecules [144]. The VEGF and 
platelet-derived growth factor (PDGF) families of proteins and their receptors (VEGFR-1, 
VEGFR-2, VEGFR-3, PDGFR-ǂ, and PDGFR-ǃ) appear central to the process [144]. 
Activation of VEGFRs and PDGFRs initiates signaling that results in numerous cellular 
responses, including survival, mitogenesis, migration, proliferation, and differentiation [144-
145]. Activation of the VEGF pathway also increases vascular permeability and the 
movement of endothelial progenitor cells from the bone marrow into the peripheral 
circulation [144]. Primary breast tumors express a variety of different angiogenic factors, 
with VEGF being the most abundant. 
High VEGF expression appears to be correlated with poor clinical prognosis and response 
[146]. Levels of VEGF in breast cancer tumors are a prognostic factor for relapse-free and 
www.intechopen.com
 
Signal Transduction Pathways in Breast Cancer – Drug Targets and Challenges 121 
overall survival in patients with both lymph node–negative and lymph node–positive 
disease [147-148], and they predict response to both tamoxifen and chemotherapy in 
advanced disease [149]. Similarly, a proportion of invasive breast cancers that over-express 
PDGFR-ǂ have been associated with greater biological aggressiveness and a higher 
likelihood of lymph node metastasis [150]. 
Given their central roles in tumor angiogenesis and growth, the VEGF and PDGF signaling 
pathways are key targets for breast cancer therapy. However, with considerable redundancy 
in angiogenic signaling pathways, the inhibition of more than one receptor is likely 
necessary to block angiogenesis. It has been hypothesized that anti-VEGF agents may 
prevent the development of new tumor vasculature and induce normalization of existing, 
inefficient tumor vasculature (resulting from over-expression of VEGF) [151]. These agents, 
then, may allow better delivery of cytotoxic therapies to the tumor, suggesting a potential 
role for anti-VEGF therapy in conjunction with chemotherapy [151-152]. 
2.14 STIs-7: Targeted therapies directed at angiogenesis 
Several therapies targeting angiogenesis are in development for breast cancer. These include 
monoclonal antibodies that act extracellularly by binding to receptors or their ligands, such 
as bevacizumab (Avastin®), and RTKIs that act intracellularly, such as sunitinib (Sutent®). 
Intracellular VEGF targeting therapeutics will be discussed later as they were proven to be 
targeting multiple sites. 
Monoclonal antibodies: Bevacizumab 
Bevacizumab is an anti-VEGF humanized monoclonal antibody administered as an i.v. 
infusion. It acts by binding to all VEGF isoforms, thus removing VEGF from the circulation 
and preventing activation of VEGFRs [153]. In 2008, the U.S. Food and Drug Administration 
(FDA) approved bevacizumab in combination with paclitaxel for the first-line treatment of 
locally recurrent breast cancer or MBC [7].  
Although bevacizumab has shown little activity as a single agent in MBC patients, 
combination therapy with chemotherapeutic agents has been associated with clinical 
activity in this patient population. Several phase III studies have investigated 
bevacizumab combined with chemotherapy [154-155]. These data suggest that VEGF 
inhibition combined with chemotherapy is a promising treatment strategy in this setting. 
Further studies are under way to explore the use of bevacizumab with different 
chemotherapeutic regimens, hormonal treatments, and other targeted therapies (including 
lapatinib and trastuzumab) in patients with MBC. Additionally, trials of bevacizumab are 
ongoing in the adjuvant and neoadjuvant settings, and preliminary reports suggest that 
this approach may be feasible.  
Hypertension, bleeding, and thrombosis remain potential safety concerns with a number of 
anti-VEGF therapies, and this area requires further study. Future trials should focus on 
identifying those patients who will derive the most benefit from bevacizumab- based 
regimens and how best to combine bevacizumab with other cancer therapies (which 
therapies should be combined and whether sequential or concurrent administration is most 
effective). Overall, growing clinical experience with agents targeting angiogenic processes, 
such as bevacizumab, has provided proof of concept for the use of these treatments in MBC 
patients [7]. 
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2.15 STPs-8: Multi-target therapeutics 
There appears to be extensive crosstalk between the pathways driving tumorigenic 
processes, and this provides a good rationale for inhibiting multiple pathways and 
processes with multi-targeted agents, either as single agents or in combination [7]. A 
number of single-agent RTKIs with multiple molecular targets have been developed as an 
alternative to combining multiple agents. These were developed based on previous studies 
showing that combining agents that target different pathways may have synergistic activity 
and delay or reverse resistance [156-158]. 
2.16 STIs-8: Multi-target inhibitors 
A range of oral, antiangiogenic RTKIs with multiple targets is currently in development for 
MBC. These include sunitinib, pazopanib, sorafenib (Nexavar®) and axitinib. 
Sunitinib selectively inhibits several receptor tyrosine kinases (VEGFR-1, VEGFR-2, 
VEGFR-3, PDGFR- ǂ, PDGFR-ǃ, Kit, FMS-like tyrosine kinase [FLT]-3, and colony-
stimulating factor 1 receptor). It has both anti-angiogenic and anti-tumor activities. Sunitinib 
has been shown to have antitumor activity in breast cancer preclinical studies, both as a 
single agent and in combination with chemotherapy [159-163]. 
Data from a phase II study of sunitinib monotherapy in patients with refractory MBC 
reported single-agent activity in heavily pretreated patients, previously exposed to an 
anthracycline and a taxane [164]. The toxicities were manageable [164]. Studies and case 
series evaluating sunitinib given in combination with taxane therapy for MBC have reported 
antitumor activity and a manageable and tolerable safety profile [165-166]. Phase III trials of 
sunitinib in combination with a variety of cytotoxic agents are under way in first- and 
second-line MBC therapy [7].  
Pazopanib targets VEGFR, PDGFR, and Kit and is currently in development in a number of 
tumor types, including breast cancer. Although originally developed as a Raf inhibitor, 
sorafenib also inhibits the activity of VEGFR-2 and VEGFR-3, PDGFR-ǃ, FLT-3, and Kit; 
thus, it may inhibit tumor growth both directly (through Raf and Kit) and indirectly, 
through inhibition of angiogenesis [167-168].  
Sorafenib inhibited MAPK activity in breast cancer cell lines expressing mutations of K-
Ras or B-Raf, and showed antitumor and antiangiogenic activity in a human breast cancer 
xenograft model [168]. Significant and sustained increases in blood pressure were 
reported in a study of sorafenib monotherapy in patients with metastatic solid tumors 
[169]. Current data suggest little activity for sorafenib as a single agent in MBC patients; 
ongoing studies are exploring combination treatment with paclitaxel and with anastrozole 
in MBC. 
Axitinib inhibits all known VEGFRs, in addition to PDGFR-ǃ and the stem cell factor 
receptor Kit, and is currently being investigated in a range of tumor types, including breast 
cancer. In preclinical studies, axitinib was shown to selectively block VEGF-stimulated 
receptor phosphorylation in vitro, resulting in the inhibition of endothelial cell proliferation 
and survival. In a human breast cancer xenograft model, it significantly inhibited tumor 
growth and disrupted tumor microvasculature as assessed by dynamic contrast-enhanced 
magnetic resonance imaging [170].  
To date, the mult-itargeted RTKIs discussed have not been validated in phase III trials in 
MBC patients, although there is preliminary evidence of clinical activity. Of the four agents 
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described above, three (pazopanib, sunitinib, and axitinib) appear to have the most clinical 
activity to date. Based on experience with other targeted agents in breast cancer, and with 
these RTKIs in other indications, combinations will hopefully show greater efficacy in the 
treatment of breast cancer [7]. 
2.17 STPs-9: Estrogen signaling transduction 
Two of the genetic subtypes in breast cancer so far identified are those with gene expression 
characteristics typical of basal epithelial cells (which are predominantly estrogen receptor 
[ER-) and those with gene expression characteristics typical of luminal epithelial cells (which 
are predominantly ER+) [14, 171]. Typically, tumors of the ER-, basal subtype are associated 
with shorter relapse-free and overall survival times than those of the ER+, luminal subtype 
[171]. 
2.18 STIs-9: Estrogen signaling inhibitors 
Endocrine therapy is widely used in the treatment of both early stage and recurrent/metastatic 
breast cancer. Tamoxifen and estrogen deprivation therapies such as aromatase inhibitors 
(AIs) and ovarian suppression have proved clinically effective and are generally well tolerated; 
they are the primary reason for the sustained improvement in survival for patients with early-
stage [ER+] breast cancer [172]. Their long-term efficacy, however, is limited by relapse of 
disease and development of resistance following adjuvant endocrine therapy. This provides a 
strong rationale for using targeted agents against various growth factor and signaling 
pathways that are activated during endocrine resistance and for combining these targeted 
agents with ongoing endocrine therapy to either overcome endocrine resistance and enhance 
the efficacy of therapy for ER-positive breast cancer [173-174]. 
In this context, several selected targeted agents are being investigated in combination with 
endocrine therapy for patients with breast cancer in an attempt to overcome or prevent 
endocrine resistance. The role of EGFR/HER2 cross-talk with estrogen receptor (ER) 
signaling has been confirmed in preclinical studies [175] in which various inhibitors have 
yielded additive or synergistic effects when combined with endocrine agents. Recently, 
several results from clinical trials investigating this concept have been reported [59, 92]. 
2.19 STPs-10 
Cancer progression is a multi-step process that enables tumor cells to invade through 
extracellular tissues and metastasize to distal organs [8]. Compelling recent evidence 
demonstrates that cooperation between signals from the extracellular matrix (ECM) and 
growth factors enhances malignant behaviors of aggressive cancer cells, such as proliferation, 
migration, survival, and invasion [176]. Examples of such cross talk signals include: 
a. The STATs are a family of transcription factors that relay the interactions of cytokines 
and growth factors with their receptors at the cell surface to mediate changes in gene 
expression. In normal situations STATs are transiently activated; however, in many 
tumors tyrosine-phosphorylated STATs, mainly STAT3 and STAT5, can be detected, 
suggesting constitutive pathway activation [6].  
b. The NF-κB pathway is triggered in response to microbial and viral infections and to 
pro-inflammatory cytokines. These agents activate the IκB kinase, which phosphoylates 
IκB allowing the liberated NF-κB family transcription factors to enter the nucleus. The 
pathway has an ever increasing interest for its role in human cancer [177]. The 
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association of NF-κB pathway activity with inflammation-associated tumor progression 
is well documented in mouse tumor models [178] and in human cancer cells [179]. 
c. The Notch network in mammals consists of four Notch receptors and five ligands. 
Once activated, the receptor undergoes intramembrane proteolysis leading to release 
and nuclear translocation of the intracellular domain, which has transcriptional activity. 
The Notch-4 gene is frequently rearranged in mammary glands by MMTV proviral 
integration. This rearrangement leads to expression of the intracellular domain under 
MMTV promoter control [180] an early demonstration of Notch’s ability to induce 
mammary cancer. 
d. The UPS pathway: The ubiquitin proteasome system (UPS) consists of several crucial 
enzymes contributing to most, if not all, cellular events. During the past decade, 
progress in endocrine therapy and the use of trastuzumab has significantly contributed 
to the decline in breast cancer mortality for hormone receptor-positive and HER2-
positive cases, respectively. As a result of these advances, a breast cancer cluster with 
poor prognosis that is negative for the estrogen receptor (ER1), the progesterone 
receptor (PRGR) and HER2 (triple negative; basal like phenotype) has come to the 
forefront of medical therapeutic attention. DNA microarray analyses have revealed that 
this cluster is phenotypically most like the basal-like breast cancer that is caused by 
deficiencies in the BRCA1 pathways. BRCA1 acts as a hub protein that coordinates a 
diverse range of cellular pathways to maintain genomic stability [181]. Indeed, BRCA1 
dysfunction in sporadic basal-like cancers has been reported [182]. Thus, investigating 
the BRCA1 pathway could be an important approach for the treatment of basal-like 
breast cancer. 
2.20 STIs-10 
To gain further improvements in breast cancer survival, new types of drugs might be 
required, and small molecules targeting the ubiquitin proteasome system have moved into 
the spotlight. The success of bortezomib in the treatment of multiple myeloma has sent 
encouraging signals that proteasome inhibitors could be used to treat other types of cancers 
[183]. In addition, ubiquitin enzymes involved in ER1, HER2 or BRCA1 pathways could be 
ideal targets for therapeutic intervention. The therapeutic effect of proteasome inhibitors on 
breast cancer remains to be determined but is greatly anticipated [184]. 
3. Targeting molecular signal in breast cancer stem cells responsible for 
development of multi-drug resistance (MDR) 
Success in Breast cancer chemotherapy is challenged by the development of tumors having a 
multi-drug resistance (MDR) phenotype [185]. It is one of the major causes of failures to 
cancer chemotherapy. This phenotype is most prevalent in aggressive carcinomas as breast 
and ovarian carcinomas. By definition, MDR is a term used to describe the resistance 
developed by some tumors to protect themselves against a number of structurally and 
functionally unrelated chemotherapeutic agents. MDR is not only referred to the drug with 
which the patient has been treated but also to a wide range of other drugs used in cancer 
chemotherapy [186].  
Acquired drug resistance arises from exposure of tumor cells to chemotherapeutic agents. 
Random spontaneous mutations, acceleration of proliferation rate and alteration of cell  
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sensitivity to growth factors can occur in tumor cells under the influence of cytotoxic drugs. 
On the other hand, MDR does not only develop as the result of treatment of tumor cells by a 
drug. It may be intrinsic, i.e. connected with the type of cell differentiation or genetic profile 
of tumor cells [187].  
Studies of resistance of tumor cells to cytotoxic drugs are necessary for understanding the 
mechanisms for restoring back their sensitivity. Although, MDR is a multi-factorial problem 
i.e. multiple mechanisms were hypothesized to account for this phenomenon, some of them 
were frequently observed and their clinical significance was determined. These mechanisms 
are acting either alone or in concert with each other for the development of the MDR 
phenotype in breast cancer cells [188]. Over-expression of ABC transporters, detoxification 
enzymes (aldehyde dehydrogenase), low cell turn over rate and the ability to activate the 
DNA check point response are possibly all involved and previously described with other 
mechanisms [189]. Innovative therapies, based on a better understanding of cancer stem 
cells, should lead to enhanced and long-term cure rates in breast cancer. 
Given that tumor resistance to chemotherapy is believed to account for the majority of 
treatment failure in breast cancer, research attention in the last two decades focused on 
developing agents to reverse MDR and enhance the response of tumors to chemotherapeutic 
agents. Although hundreds of compounds have been found in-vitro to be able to modulate 
the MDR phenotype, their clinical application was limited owing to their high toxicity in-
vivo [190-191]. Accordingly, searching for compounds able to modulate the MDR phenotype 
and have low toxicity continues to be an important challenge for optimizing cancer 
chemotherapy. The development of several therapeutics targeting the MDR phenotype in 
breast cancer cells have been previously reviewed [189].  
Recently, the possible roles of cancer stem cells in carcinogenesis have become more 
obvious. Numerous investigations have recently provided evidence that the genetic 
alterations occurring in the multi-potent tissue-specific adult stem cells and/or their early 
progenies may lead to their malignant transformation into cancer progenitor cells also 
designated as cancer stem cells or cancer-initiating cells [192]. A small population of 
undifferentiated- or poorly differentiated cancer progenitor cells, which possesses the stem 
cell-like properties including their self-renewal ability and capacity to give rise to the bulk 
mass of further differentiated malignant cells, appears to represent the principal cancer cells 
that are responsible for tumor formation [193]. Accumulating genetic alterations in 
tumorigenic cancer progenitor cells occurring during cancer progression may also confer to 
them the invasive and resistant properties that are essential for their remission and 
migration to distant metastatic sites [194-195].  
The role of cancer stem cells in breast cancer chemoresistance was recently reviewed [196]. 
One characteristic of cancer stem cells that differentiates them from other normal cells in the 
tumor is that they have high levels of ABC transporter proteins, in particular ABCG2 [197]. 
The ABC transporter molecules are responsible for protecting cells from drug damage via 
efflux pumping mechanisms. Thus, cancer stem cells, as a result of these biological 
properties, are rendered resistant to drug treatment, including chemotherapeutic drugs 
[198]. 
Since all the stem cell-like properties attributed to cancer progenitor cells may provide them 
with a higher resistance to current cancer therapies, thus they constitute a substantial 
obstacle to the successful treatment of cancer patients [196]. This finding underlines the 
critical importance of targeting the cancer progenitor cells and their early progenies as well 
as their local microenvironment in the earlier stages of cancer treatment to counteract the 
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rapid progression of certain cancer types and prevent the metastatic spread at distant sites. 
The simultaneous blockade of several oncogenic cascades activated in cancer progenitor 
cells during cancer progression may be essential for improving the current clinical 
treatments against high-risk, metastatic or relapsed breast cancers [189, 199].  
Recent studies have revealed the possibility of using therapeutic agents targeting the EGFR, 
Wnt/ǃ-catenin and/or Notch cascades to inhibit the ABC muli-drug efflux transporters 
and/or eliminate the cancer progenitor cells [200]. Moreover, one compound, salinomycin, 
reduces the proportion of cancer stem cells by >100-fold relative to paclitaxel, a commonly 
used breast cancer chemotherapeutic drug [201]. In addition, treatment of mice with 
salinomycin inhibits mammary tumor growth in vivo and induces increased epithelial 
differentiation of tumor cells [199]. What remains to be discovered is the extensive and in 
depth understanding of the molecular basis of cancer stem cell contribution to breast cancer 
development. Such extensive investigations enable the development of more effective and 
selective treatment strategies. 
4. Concluding remarks and perspectives 
Considerable progress has been made over the last several decades in understanding 
specific cellular, molecular and genetic mechanisms that contribute to cancer growth and 
progression [202]. In recent years, research efforts have focused on the signaling pathways 
involved in the growth and survival of breast cancer cells, leading to the development of a 
range of targeted agents with promising clinical activity. The encouraging success of 
trastuzumab, based on the identification of HER-2 as a molecular target, has provided the 
rationale for studying the array of targeted agents currently in clinical development for 
breast cancer [7]. 
We have reviewed some of the most promising new targeted agents in breast cancer. This 
list, however, is far from complete. It should be pointed out that there are still many 
important additional classes of agents in clinical development in breast cancer. Examples 
include other tyrosine kinase inhibitors and also enhancers of apoptosis. We all hope that 
this list will keep developing. However, despite recent advances, there are still unanswered 
questions regarding the management of breast cancer with targeted agents. 
With our knowledge of the molecular modifications in breast cancer and the increasing 
number of new targeted therapeutics, the current challenge is to select the best combinations 
of the so-called signal transduction inhibitors (STIs) for every patient [6]. The development 
of these targeted therapeutics will require a new set of challenging skills & investigations of 
unresolved issues [120]. These challenges are:  
First, future studies are necessary to identify those patient subgroups likely to derive most 
benefit from a given therapy. Despite the temptation to use a targeted agent in all patients, 
identification of patient subgroups most likely to benefit must be a key goal and will be 
critical to the successful future use of these treatments [7]. These agents, unlike 
chemotherapy, will only work in the subset of tumors that show dependency on the target 
the therapy is being directed to. 
If STI would have been developed in an unselected patient population, its anti-tumor 
activity would have been missed due to a dilutional effect brought in by the non-STPs-over-
expressing population. This principle probably applies to the majority of classes of agents 
under study. The implication of this principle is that patient selection strategies will be of 
paramount importance in the development of these agents [120]. For example, accurate 
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patient selection based on HER-2 over-expression is essential for trastuzumab-based 
treatment and is likely to be important for other agents in this class. However, identifying 
suitable patients may prove more difficult for RTKIs, because receptor over-expression 
alone does not seem to predict response to treatment [16]. 
Second, future studies are necessary to determine the optimal combinations, doses, and 
schedules required to maximize clinical activity while minimizing toxicity. Also, in early 
clinical studies with these agents in addition to establishing their safety and optimal doses 
and schedules, it may prove to be instrumental to also check for the presence of the target in 
the studied tumors and to seek for indications of target engagement with the study agent 
using careful analysis of [120]2007). The need to determine target engagement is currently 
being taken into account with the majority of clinical trials with novel agents that are moved 
into the clinic. 
Third, Predictive markers are factors that are associated with upfront response or resistance 
to a particular therapy. Predictive markers are important in oncology as tumors of the same 
tissue of origin vary widely in their response to most available systemic therapies. Currently 
recommended oncological predictive markers include both estrogen and progesterone 
receptors for identifying patients with breast cancers likely to benefit from hormone 
therapy, HER-2 for the identification of breast cancer patients likely to benefit from 
trastuzumab [203]. Thus, the drive to identify new biomarkers of target engagement and 
sensitivity with these novel agents is also promoting the search for new clinical study 
designs in a minimally pre-treated population [120]. 
Fourth, future studies will need to address how best to incorporate these agents into 
existing treatment regimens and to determine when and in which combinations targeted 
therapy should be administered [7]. Some of these agents will have limited activity by 
themselves and yet have the capacity to markedly enhance the anti-tumor activity of 
conventional agents like chemotherapy or even other biological agents. For example, anti 
angiogenesis MAb bevacizumab that has no activity as a single agent and yet is clinically 
active when combined with chemotherapy. Furthermore, HER-targeted agents may need to 
be used in combination with chemotherapy to provide clinically relevant activity. 
Fifth, the therapy end-points with these agents also need to be revisited. Some of these 
agents are not expected to result in tumor shrinkage (or response), and therefore we cannot 
propose a unified definition of clinical benefit as it has been done with chemotherapy in the 
past. Furthermore, genetic assay techniques used to provide information on clinical 
outcomes, including the risk for tumor recurrence and individual benefit from a particular 
chemotherapy also needs further critical development [204]. 
Sixth, Targeting HER-2 is associated with cardiac toxicity, which is an especially important 
consideration in the adjuvant setting and when combining anti–HER-2 agents with 
cardiotoxic chemotherapeutic drugs. Targeting HER-1 in combination with HER-2, as with 
the RTKIs lapatinib and neratinib, appears to reduce the risk for cardiotoxicity, although the 
exact mechanisms underlying this observation remain unclear [7]. 
Finally, with the increase in the number of available lines of therapy in breast cancer, there 
is a danger that novel agents will be tested in a heavily pre-treated patient population. 
While there is little debate if patients with advanced disease receiving multiple lines of 
therapy may be appropriate study participants in early clinical studies. There is also a 
growing concern that patients with advanced disease may not be the ideal population to 
detect the anti-tumor activity of novel agents since their tumors may have become highly 
resistant to any type of therapy [120]. 
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In summary, the contribution of STIs in cancer chemotherapy continues to be encouraging, 
and clinical trials are currently addressing whether the promising preclinical activities of 
STIs will translate into benefits for patients. Hopefully, the previously mentioned 
suggestions and mechanisms will ultimately be put into practice. Moreover, cellular 
responses to cancer chemotherapeutic agents are complex and several mechanisms are 
commonly associated with the resistance of laboratory human breast cancer cell lines. 
Clinical testing of breast cancer STIs like other modern day targeted therapeutics must be 
rationally developed with a firm basis in the lessons learned in the laboratory and with 
proper selection of patient populations in which the predictive power and the potential for 
benefit is greatest.  
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